$2.48
6.90% yesterday
Nasdaq, Jul 14, 10:00 pm CET
ISIN
NL0010872495
Symbol
PRQR
Sector
Industry

ProQR Therapeutics N.V. Stock price

$2.48
+0.58 30.53% 1M
+0.22 9.73% 6M
-0.17 6.42% YTD
+0.73 41.71% 1Y
+1.70 217.54% 3Y
-2.44 49.59% 5Y
-14.81 85.66% 10Y
-12.25 83.16% 20Y
Nasdaq, Closing price Mon, Jul 14 2025
+0.16 6.90%
ISIN
NL0010872495
Symbol
PRQR
Sector
Industry

Key metrics

Basic
Market capitalization
$244.1m
Enterprise Value
$109.0m
Net debt
positive
Cash
$154.5m
Shares outstanding
107.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
10.6 | 11.7
EV/Sales
4.8 | 5.2
EV/FCF
negative
P/B
2.7
Financial Health
Equity Ratio
52.7%
Return on Equity
-31.4%
ROCE
-28.2%
ROIC
420.6%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$22.9m | $20.9m
EBITDA
$-35.5m | $-62.4m
EBIT
$-38.7m | $-48.3m
Net Income
$-35.2m | $-49.5m
Free Cash Flow
$-44.3m
Growth (TTM | estimate)
Revenue
45.5% | -8.7%
EBITDA
-9.2% | -92.7%
EBIT
-8.7% | -35.6%
Net Income
-12.5% | -52.4%
Free Cash Flow
5.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-155.2% | -299.0%
EBIT
-169.2%
Net
-153.8% | -236.9%
Free Cash Flow
-193.5%
More
EPS
$-0.3
FCF per Share
$-0.4
Short interest
0.9%
Employees
166
Rev per Employee
$140.0k
Show more

Is ProQR Therapeutics N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

ProQR Therapeutics N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a ProQR Therapeutics N.V. forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a ProQR Therapeutics N.V. forecast:

Buy
93%
Hold
7%

Financial data from ProQR Therapeutics N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
23 23
46% 46%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
14% 14%
69%
- Research and Development Expense 46 46
39% 39%
201%
-36 -36
9% 9%
-155%
- Depreciation and Amortization 3.21 3.21
4% 4%
14%
EBIT (Operating Income) EBIT -39 -39
9% 9%
-169%
Net Profit -35 -35
12% 12%
-154%

In millions USD.

Don't miss a Thing! We will send you all news about ProQR Therapeutics N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ProQR Therapeutics N.V. Stock News

Neutral
GlobeNewsWire
18 days ago
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clini...
Neutral
GlobeNewsWire
2 months ago
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th An...
Neutral
GlobeNewsWire
2 months ago
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.
More ProQR Therapeutics N.V. News

Company Profile

ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Head office Netherlands
CEO Daniel Boer
Employees 166
Founded 2012
Website www.proqr.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today